Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial.

Michael TaylorJohn JefferiesBarry ByrneJoao LimaBharath Ambale-VenkateshMohammad R OstovanehRaj MakkarBryan H GoldsteinRachel Ruckdeschel SmithJames FudgeKonstantinos MalliarasBrian FedorJeff RudyJanice M PogodaLinda MarbánDeborah D AscheimEduardo MarbánRonald G Victor

Published in: Neurology (2019)

This phase I/II study provides Class II evidence that for patients with DMD, intracoronary CAP-1002 is feasible and appears safe and potentially effective.

Keyphrases

skeletal muscle
phase iii
phase ii
muscular dystrophy
open label
double blind
clinical trial
insulin resistance
study protocol
left ventricular
randomized controlled trial
metabolic syndrome
type diabetes
st elevation myocardial infarction
atrial fibrillation